Cargando…

NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions

The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the safety and efficacy of non valvular atrial fibrillation treatment for stroke prevention, with significant reducti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Cesare, Mariachiara, Jarvis, Jordan D., Scarlatescu, Oana, Leng, Xinyi, Zaidel, Ezequiel J., Burrone, Esteban, Eiselé, Jean-Luc, Prabhakaran, Dorairaj, Sliwa, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ubiquity Press 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546116/ https://www.ncbi.nlm.nih.gov/pubmed/33150132 http://dx.doi.org/10.5334/gh.774

Ejemplares similares

Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality
por: Zaidel, Ezequiel J., et al.
Publicado: (2020)

Monographs for medicines on WHO’s Model List of Essential Medicines
por: Roth, Lukas, et al.
Publicado: (2018)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Evaluating equality in prescribing Novel Oral Anticoagulants (NOACs) in England: The protocol of a Bayesian small area analysis
por: Rezaei-Darzi, Ehsan, et al.
Publicado: (2021)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

WHO’s 7 policy recommendations on building resilient health systems
Publicado: (2021)

Reversal agents for NOACs: Connecting the dots
por: Dalal, Jamshed, et al.
Publicado: (2016)

Who’s in and Who’s Out? Selection Bias in Aging Research
por: Mayeda, Elizabeth Rose, et al.
Publicado: (2020)

Disparities in access to fertility care: who’s in and who’s out
por: Galic, Isabel, et al.
Publicado: (2020)

Unlocking the WHO’s Age-Friendly Healthcare Principles: Portugal’s Quest and Recommendations
por: Tavares, Jéssica, et al.
Publicado: (2023)

Who’s Who
Publicado: (2022)

The World Heart Observatory: Harnessing the Power of Data for Cardiovascular Health
por: Perel, Pablo, et al.
Publicado: (2022)

DVT prophylaxis in critical care: role of NOACS
por: Lancé, Marcus D.
Publicado: (2019)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

Countries’ response to WHO’s travel recommendations during the 2013–2016 Ebola outbreak
por: Rhymer, Wendy, et al.
Publicado: (2017)

Who’s got TALENT?
por: Joannah Caborn Wengler
Publicado: (2012)

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

A Systematic Review of the Basis for WHO’s New Recommendation for Limiting Aircraft Noise Annoyance
por: Gjestland, Truls
Publicado: (2018)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding
por: Lee, Min-Taek, et al.
Publicado: (2020)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
por: Saviano, Angela, et al.
Publicado: (2022)

Cool, but who’s going to pay for that
por: CERN. Geneva
Publicado: (2011)

Introduction to Who’s Who: EBCOG
por: Van Wiemeersch, J.
Publicado: (2010)

Who’s afraid of response bias?
por: Peters, Megan A. K., et al.
Publicado: (2016)

Longevity or hypoxia: who’s driving?
por: Pamenter, Matthew E., et al.
Publicado: (2019)

Rehabilitation in the context of WHO’s mandate
por: Ghebreyesus, Tedros Adhanom
Publicado: (2022)

Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
por: Singh, Balbir, et al.
Publicado: (2022)

Community Vs. hospital HIV testing sites in Jerusalem, Israel - who’s tested and who’s at risk?
por: Atias, Dor, et al.
Publicado: (2020)

Scientific Opinion on the update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA
por: Ricci, Antonia, et al.
Publicado: (2017)

WHF Recommendations for the Use of Echocardiography in Chagas Disease
por: Ralston, Kate, et al.
Publicado: (2023)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?
por: Yang, Hayang, et al.
Publicado: (2017)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

Who’s a Good Boy? Effects of Dog and Owner Body Weight on Veterinarian Perceptions and Treatment Recommendations
por: Pearl, Rebecca L., et al.
Publicado: (2020)

Non-adherence to WHO’s recommended 8-contact model: geospatial analysis of the 2017 Maternal Health Survey
por: Dickson, Kwamena Sekyi, et al.
Publicado: (2023)

Tumor-stroma relationships: Who’s the driver?
por: Wooster, Richard F.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ca8ede0sr6ehls4l1q7uvmm8g8